272 Capital LP Cuts Position in Definitive Healthcare Corp. (NASDAQ:DH)

272 Capital LP cut its holdings in shares of Definitive Healthcare Corp. (NASDAQ:DH - Free Report) by 39.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 677,940 shares of the company's stock after selling 436,140 shares during the quarter. Definitive Healthcare makes up approximately 2.6% of 272 Capital LP's portfolio, making the stock its 15th largest holding. 272 Capital LP owned 0.59% of Definitive Healthcare worth $2,786,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC grew its holdings in Definitive Healthcare by 3,652.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company's stock valued at $29,000 after buying an additional 6,794 shares in the last quarter. Ieq Capital LLC purchased a new position in Definitive Healthcare during the fourth quarter valued at approximately $51,000. KLP Kapitalforvaltning AS bought a new stake in Definitive Healthcare during the 4th quarter worth approximately $54,000. Two Sigma Securities LLC purchased a new stake in Definitive Healthcare in the 4th quarter worth approximately $56,000. Finally, Quantbot Technologies LP boosted its holdings in Definitive Healthcare by 5,305.5% in the 4th quarter. Quantbot Technologies LP now owns 17,730 shares of the company's stock valued at $73,000 after purchasing an additional 17,402 shares during the period. Institutional investors own 98.67% of the company's stock.

Definitive Healthcare Trading Up 3.3 %

NASDAQ:DH traded up $0.09 during trading hours on Friday, reaching $2.84. The company's stock had a trading volume of 369,226 shares, compared to its average volume of 856,100. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. The firm has a market capitalization of $306.61 million, a price-to-earnings ratio of -0.92, a PEG ratio of 4.06 and a beta of 1.48. The firm has a 50-day simple moving average of $2.79 and a 200-day simple moving average of $3.92. Definitive Healthcare Corp. has a 1 year low of $2.15 and a 1 year high of $7.47.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The company had revenue of $62.29 million during the quarter, compared to analysts' expectations of $60.60 million. Research analysts expect that Definitive Healthcare Corp. will post 0.16 EPS for the current fiscal year.

Analyst Ratings Changes

DH has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Barclays dropped their price target on Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research report on Monday, March 3rd. Finally, The Goldman Sachs Group decreased their price objective on shares of Definitive Healthcare from $4.50 to $3.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $5.35.

Definitive Healthcare Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.